Mantle Cell Lymphoma

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses acalabrutinib (Calquence) in mantle cell lymphoma.

The United Kingdom's National Institute for Health Care and Excellence has published new guidelines recommending ibrutinib as treatment for patients with relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, discusses the impact of acalabrutinib on patients with mantle cell lymphoma, ongoing progress in the field, and The University of Texas MD Anderson Cancer Center

Andre Goy, MD, sheds light on some studies as well as future treatment options for patients with mantle cell lymphoma (MCL).

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses results from the phase II ACE-LY-004 trial, which explored the BTK inhibitor acalabrutinib (Calquence) in patients with refractory mantle cell lymphoma (MCL).

Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses single-agent ibrutinib (Imbruvica) in mantle cell lymphoma.

Lenalidomide (Revlimid) plus rituximab (Rituxan) is a feasible combination that is also safe and active, as initial and maintenance therapy for patients with mantle cell lymphoma.